Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19250642rdf:typepubmed:Citationlld:pubmed
pubmed-article:19250642lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:19250642lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:19250642lifeskim:mentionsumls-concept:C0035331lld:lifeskim
pubmed-article:19250642lifeskim:mentionsumls-concept:C0282548lld:lifeskim
pubmed-article:19250642lifeskim:mentionsumls-concept:C0769628lld:lifeskim
pubmed-article:19250642pubmed:issue2lld:pubmed
pubmed-article:19250642pubmed:dateCreated2009-3-9lld:pubmed
pubmed-article:19250642pubmed:abstractTextRetinal leukostasis, mediated by intracellular adhesion molecule-1 (ICAM-1) and vascular endothelial growth factor (VEGF), has been implicated in the pathogenesis of early diabetic retinopathy. Phosphomannopentaose sulfate (PI-88) is a highly sulfonated oligosaccharide which inhibits heparanase activity and competes with heparan sulfate binding to growth factors. In this study, we evaluated whether PI-88 could inhibit retinal leukostasis in strepotzotocin(STZ)-induced diabetic rat and elucidated the possible mechanisms. Diabetes was induced in Sprague-Dawley rats by intraperitoneal injection (i.p.) of STZ. Three months after induction, diabetic rats were administered PI-88 (25 mg/kg body weight) or vehicle solution daily via i.p. for 14 consecutive days. Leukostasis was analyzed on retinal flatmounts by concanavalin A and CD45 immunofluorescence staining. Retinal function was analyzed by electroretinography (ERG). ICAM-1 and VEGF levels in retinas were studied by Western blot and enzyme-linked immunosorbent assay (ELISA) respectively. The systemic administration of PI-88, but not vehicle, significantly decreased the number of adherent leukocytes in retinas by 52.24% (P<0.001) and led to significant preservation (about 50%, P<0.001) of scotopic ERG a- and b-wave amplitudes in treated diabetic rats as compared to those of diabetic control rats. These changes were associated with downregulation of ICAM-1 (45%, P<0.001) and VEGF (26.83+/-2.01 versus 40.8+/-3.24 pg/mg, P<0.01) in retinas of PI-88 treated diabetic rats as compared to those of diabetic control rats. PI-88 significantly inhibited retinal leukostasis and reversed retinal dysfunction by a mechanism that may include decreased ICAM-1 and VEGF expression in diabetic rats. Our data suggests that PI-88 is a promising agent for the treatment of diabetic retinopathy.lld:pubmed
pubmed-article:19250642pubmed:languageenglld:pubmed
pubmed-article:19250642pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19250642pubmed:citationSubsetIMlld:pubmed
pubmed-article:19250642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19250642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19250642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19250642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19250642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19250642pubmed:statusMEDLINElld:pubmed
pubmed-article:19250642pubmed:monthMarlld:pubmed
pubmed-article:19250642pubmed:issn1090-2104lld:pubmed
pubmed-article:19250642pubmed:authorpubmed-author:HuJieJlld:pubmed
pubmed-article:19250642pubmed:authorpubmed-author:TangShiboSlld:pubmed
pubmed-article:19250642pubmed:authorpubmed-author:LuoYanYlld:pubmed
pubmed-article:19250642pubmed:authorpubmed-author:MaPingpingPlld:pubmed
pubmed-article:19250642pubmed:authorpubmed-author:ZhuXiaoboXlld:pubmed
pubmed-article:19250642pubmed:authorpubmed-author:MaHongjieHlld:pubmed
pubmed-article:19250642pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19250642pubmed:day6lld:pubmed
pubmed-article:19250642pubmed:volume380lld:pubmed
pubmed-article:19250642pubmed:ownerNLMlld:pubmed
pubmed-article:19250642pubmed:authorsCompleteYlld:pubmed
pubmed-article:19250642pubmed:pagination402-6lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:meshHeadingpubmed-meshheading:19250642...lld:pubmed
pubmed-article:19250642pubmed:year2009lld:pubmed
pubmed-article:19250642pubmed:articleTitlePhosphomannopentaose sulfate (PI-88) inhibits retinal leukostasis in diabetic rat.lld:pubmed
pubmed-article:19250642pubmed:affiliationState Key Laboratory of Ophthalmology, Zhongshan Opthalmic Center, Sun Yat-sen University, 54S, Xianlie Road, Guangzhou 510060, China.lld:pubmed
pubmed-article:19250642pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19250642pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed